Applaud Medical Appoints Paul Molloy as Chief Executive Officer and a Member of the Company’s Board of Directors
SAN FRANCISCO--Applaud Medical, an emerging leader in the treatment of urinary stone disease, announced today the appointment of industry veteran Paul Molloy (Molloy) as Chief Executive Officer (CEO). The company has also added Molloy to its Board of Directors....
Applaud Medical Receives FDA Breakthrough Device Designation for the Company’s Acoustic Enhancer for Use in Conjunction With Ureteroscopy With Laser Lithotripsy (URS-LL) for the Fragmentation of Calcium-Based Kidney Stones
SAN FRANCISCO--Applaud Medical, Inc. (Applaud), an emerging leader in the treatment of kidney stones, today announced that its Acoustic Enhancer technology has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Acoustic...
Applaud Medical Completes Series B Funding Round
SAN FRANCISCO--Applaud Medical, Inc. (Applaud), an emerging leader in the treatment of kidney stones, today confirmed that it had successfully raised an additional $7.1M in financing, led by Gudu Medical, for the company's Series B round. With this investment, the...
Applaud Medical selected by MedTech Innovator as one of Top 50 Medtech Startups
LOS ANGELES, CA – MedTech Innovator, the largest accelerator of medical device companies in the world, today announced the 50 companies selected to participate in the organization’s flagship four-month Showcase and Accelerator program, featuring the industry’s most...
Applaud Medical Announces First Patient Enrolled in IDE Study
SAN FRANCISCO--Applaud Medical, Inc. (Applaud), an emerging leader in the treatment of kidney stones, today announced announced enrollment of the first patient in the company's prospective, multicenter, randomized, double-blind AEROLITH (Acoustic Enhancer Research on...
Applaud Medical Granted New U.S. Patent for the Company’s Acoustic Enhancer Techonology
SAN FRANCISCO--Applaud Medical, Inc. (Applaud), an emerging leader in the treatment of kidney stones, today announced that a new U.S. patent titled “Phospholipid compounds and formulations” (patent number 10,953,023) was granted to the company by the United States...
Applaud Medical Announces Announces Approval of Investigational Device Exemption (IDE) for Pivotal Study
SAN FRANCISCO--Applaud Medical, Inc. (Applaud), an emerging leader in the treatment of kidney stones, today announced it has received approval of an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to proceed with a pivotal study...